Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

By Beer T.M.   Eilers K.M.   Garzotto M.   Egorin M.J.   Lowe B.A.   Henner W.D.   Hsieh J.T.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 4, 2003-07 ,pp. : 314-315

Elsevier

Access to resources Recommend Favorite

Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer

By Sorscher Steven  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 2, 2004-08 ,pp. : 191-192

Springer Publishing Company

Access to resources Recommend Favorite

Nab‐paclitaxel‐based compared to docetaxel‐based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck

By  

Cancer Medicine, Vol. 4, Iss. 4, 2015-04 ,pp. : 481-489

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy

By Du Jun   Yang Qing   Chen Xu-Sheng   Tian Jie   Yao Xin  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1055-1061

Springer Publishing Company

Access to resources Recommend Favorite

Androgen-independent Prostate Cancer

By Hernes Eivor   Fosså Sophie D.   Skovlund Eva  

Acta Oncologica, Vol. 42, Iss. 7, 2003-11 ,pp. : 749-755

Informa Healthcare

Access to resources Recommend Favorite